Neville Rodie & Shaw Inc. Has $6.48 Million Stock Position in Abbott Laboratories $ABT

Neville Rodie & Shaw Inc. decreased its position in shares of Abbott Laboratories (NYSE:ABT) by 1.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 47,670 shares of the healthcare product maker’s stock after selling 550 shares during the period. Neville Rodie & Shaw Inc.’s holdings in Abbott Laboratories were worth $6,484,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Kelly Financial Services LLC acquired a new stake in shares of Abbott Laboratories in the first quarter worth about $216,000. Bank Pictet & Cie Europe AG lifted its position in shares of Abbott Laboratories by 1.9% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker’s stock worth $17,274,000 after buying an additional 2,774 shares during the last quarter. Edge Financial Advisors LLC lifted its position in shares of Abbott Laboratories by 3.3% in the first quarter. Edge Financial Advisors LLC now owns 2,530 shares of the healthcare product maker’s stock worth $336,000 after buying an additional 81 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new stake in shares of Abbott Laboratories in the fourth quarter worth about $84,418,000. Finally, Cerity Partners LLC lifted its position in shares of Abbott Laboratories by 49.8% in the first quarter. Cerity Partners LLC now owns 1,507,268 shares of the healthcare product maker’s stock worth $199,939,000 after buying an additional 501,200 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Transactions at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the business’s stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Trading Up 1.0%

Abbott Laboratories stock opened at $133.92 on Friday. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The firm has a market capitalization of $233.08 billion, a PE ratio of 16.78, a PEG ratio of 2.52 and a beta of 0.69. The business’s 50-day simple moving average is $130.41 and its 200-day simple moving average is $131.32.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. During the same period in the previous year, the company posted $1.14 earnings per share. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on ABT shares. Evercore ISI boosted their price target on Abbott Laboratories from $140.00 to $145.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 8th. BTIG Research reduced their price target on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, July 18th. Wells Fargo & Company dropped their price objective on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating on the stock in a research note on Friday, July 18th. Leerink Partnrs upgraded Abbott Laboratories to a “hold” rating in a research note on Monday, June 16th. Finally, Mizuho lifted their price objective on Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 16th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $144.47.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.